EP0693082A1 - Immuno modulated peptide derivatives of leukokinin fragments - Google Patents
Immuno modulated peptide derivatives of leukokinin fragmentsInfo
- Publication number
- EP0693082A1 EP0693082A1 EP94913125A EP94913125A EP0693082A1 EP 0693082 A1 EP0693082 A1 EP 0693082A1 EP 94913125 A EP94913125 A EP 94913125A EP 94913125 A EP94913125 A EP 94913125A EP 0693082 A1 EP0693082 A1 EP 0693082A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- glu
- group
- aminoacid
- fmoc
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 52
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 69
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims description 47
- 235000001014 amino acid Nutrition 0.000 claims description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 45
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 39
- 239000011347 resin Substances 0.000 claims description 36
- 229920005989 resin Polymers 0.000 claims description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 23
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 21
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 20
- -1 methylbenzhydrylamino groups Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 10
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000006386 neutralization reaction Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 6
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 claims description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical group CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002516 radical scavenger Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000005062 synaptic transmission Effects 0.000 claims description 3
- 150000003512 tertiary amines Chemical group 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000002440 hydroxy compounds Chemical class 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000001571 immunoadjuvant effect Effects 0.000 abstract description 8
- 230000003308 immunostimulating effect Effects 0.000 abstract description 8
- 239000000568 immunological adjuvant Substances 0.000 abstract description 5
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 77
- 229940024606 amino acid Drugs 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 28
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 230000001173 tumoral effect Effects 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 9
- 230000002519 immonomodulatory effect Effects 0.000 description 9
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 9
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 150000003862 amino acid derivatives Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001698 pyrogenic effect Effects 0.000 description 5
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 239000002510 pyrogen Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- MXWDHKDTQAPDQD-WZDKYTMSSA-N (2r)-n'-(1-adamantyl)-2-[[(2s)-2-aminopropanoyl]amino]pentanediamide Chemical compound C1C(C2)CC3CC2CC1(NC(=O)CC[C@@H](NC(=O)[C@@H](N)C)C(N)=O)C3 MXWDHKDTQAPDQD-WZDKYTMSSA-N 0.000 description 3
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 3
- 108010075254 C-Peptide Proteins 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010087463 adamantylamide-alanyl-isoglutamine Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 2
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108010084754 Tuftsin Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229940035423 ethyl ether Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000005826 halohydrocarbons Chemical class 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical group CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 2
- 229940035670 tuftsin Drugs 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BMJRTKDVFXYEFS-XIFFEERXSA-N (2s)-2,6-bis(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CCCCNC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 BMJRTKDVFXYEFS-XIFFEERXSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 1
- MWTAHJPEYZBMCZ-FLLNTKIGSA-N (2s)-2-aminopropanoic acid;(4r)-4,5-diamino-5-oxopentanoic acid Chemical compound C[C@H](N)C(O)=O.NC(=O)[C@H](N)CCC(O)=O MWTAHJPEYZBMCZ-FLLNTKIGSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- CVZUKWBYQQYBTF-ZDUSSCGKSA-N (4s)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxo-5-phenylmethoxypentanoic acid Chemical group CC(C)(C)OC(=O)N[C@@H](CCC(O)=O)C(=O)OCC1=CC=CC=C1 CVZUKWBYQQYBTF-ZDUSSCGKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical group OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- CVZUKWBYQQYBTF-UHFFFAOYSA-N Nalpha-tert-butoxycarbonyl-L-glutamic acid benzyl ester Natural products CC(C)(C)OC(=O)NC(CCC(O)=O)C(=O)OCC1=CC=CC=C1 CVZUKWBYQQYBTF-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical group NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 1
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003377 anti-microbal effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000007716 flux method Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical compound O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001031 immunopharmacological effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical class C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108010004914 prolylarginine Chemical group 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 108010091078 rigin Proteins 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to oligopeptide derivatives of leukokinin fragments, having immunomodulating activity, a process for their preparation and pharmaceutical compositions containing them.
- Immunomodulating agents are substances able to act on the organism natural defence, either by stimulating the immune system in case this is depressed, or by inhibiting same if it is hyperexcited.
- these compounds found a therapeutical application, for example in the immunotherapy of tumours and in the treatment of recurrent infections and allergic diseases.
- these substances are defined as immunostimulants when showing a prevailingly stimulating action and as immunoadjuvants when they are able to enhance antigens immunostimulating action.
- Immunoadjuvants can be advantageously used in the field of vaccines, if administered in association with the antigens which form the same vaccines.
- MDP muramyl dipeptide
- N-acetylmuramyl-L- alanyl-D-isoglutamine a product of bacterial origin which shows pyrogenic activity
- muramyl or desmuramyl peptides because of the presence or the absence in their structure of muramic acid residue, respectively.
- adamantyl dipeptide (AdDp)
- AdDp adamantyl dipeptide
- adamantane residue in oligopeptides imparts these compounds advantageous pharmacokinetic properties (Walder P.et al., Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP) , a muramyl dipeptide derivative in mice. Immunopharm, and Immunotoxicol . 13, PP 101-119, 1991) and in particular it improves the transfer of oligopeptides to various organs and immuno competent cells (Tsuzuki N.
- the need is felt to find new and very active compounds, which are well tolerated by organism and have a high immunostimulating and immunoadjuvant activity.
- DETAILED DESCRIPTION The Applicant has now unexpectedly found a new type of immunomodulating and immunoad uvant compounds, where the hydrophobic and metabolically stable structure of adamantane is linked to endogenous leukokinin fragments.
- the derivatives of the present invention are oligopeptide derivatives of endogenous leukokinin fragments, containing at least one residue L-Glu(NH-Ad) , and their pharmaceutically acceptable salts.
- L-Glu(NHAd) is L-glutamic acid gamma- (1- adamantylamide) ; Ad indicates the hydrocarbon residue present in
- Endogenous leukokinin are peptides of natural origin present in eukaryotic cells , for example of mammals .
- oligopeptide derivatives of leukokinin fragments we mean in the instant description oligopeptides consisting of aminoacids present in endogenous leukokinin fragments . More in particular , the present derivatives consist of oligopeptides having aminoacids in common with endogenous leukokinin fragments , in which one or more , preferably from 1 to
- L-Glu(NHAd) residues replace or alternate the aminoacids residues of these fragments .
- leukokinin fragments are 282-292 residue , also known as tuftsin (Thr-Lys-Pro-Arg) , 245-248 residue (Pro-Lys-Pro-Lys ) and 341-344 residue (Gly-Gln-Pro-Arg) .
- the aminoacid residues number in the present oligopeptides ranges from 2 to 10, preferably from 4 to 5 -
- the oligopeptides of the invention are completely different from MDP and AdDP immunomodulators, because they contain a peptidic portion of animal (mammal in particular) , rather than bacterial origin.
- oligopeptides of the invention are highly active "in vivo", in particular in stimulating the cellular and humoral immune reaction, and have a strong antiviral activity.
- the present oligopeptides have a low toxicity, rendering them well tolerated by the organism, and in particular they are not pyrogen.
- the oligopeptides of the invention are useful in the human therapy, both alone and in combination with other therapeutically active substances; for example, because of their remarkable immunomodulating, in particular immunostimulating and immunoadjuvant properties, they find application in the treatment and in the prophylaxis of diseases associated with a deficiency of the immuno response, as for example tumors and infections of various origin, for example of bacterial or viral origin, and in recurrent infections.
- the association with other therapeutically active substances concerns any kind of therapeutically suitable association, but preferably the association with substances whose activity is increased by the present oligopeptides, for example with substances having antigenic properties.
- the compounds of the present invention are therefore useful adjuvants in vaccines.
- peptides characterized by containing in the aminoacid sequence from 1 to 2 L-Glu(NHAd) residues, at least a Lys residue and at least a residue selected from the group consisting of Arg, Pro and Pro-Arg.
- More preferred derivatives are the following: H-Lys-Glu(NH-Ad)-Pro-Arg-Glu(NH-Ad)-OH (A) H-Lys-Glu(NH-Ad)-Arg-Glu(NH-Ad)-OH (B) H-Lys-Glu(NH-Ad)-Pro-Glu(NH-Ad)-OH (C) H-Glu(NH-Ad)-Lys-Pro-Arg-NH 2 (D)
- a hydrophobic residue derived from 1- aminoadamantane not only improves the oligopeptides transfer through the biological membranes and affects oligopeptides flexibility and conformation , but it also improves the bond between immunocompetent cells and cellular membranes , bringing, as a result, to a favourable pharmacokinetic profile. If compared to the known compounds , the present oligopeptides exhibit a more specific activity on the humoral immunity (see for example the compound B ) or on the cellular one ( see the compounds C and D) .
- the compounds of the invention have the advantage to be apyrogenic , more stable at the metabolism, and to exhibit a favourable pharmacokinetic profile .
- the Applicant has furthermore found that the oligopeptides of the present invention having an arginine residue at the C-terminal end (the one bearing an ⁇ -carboxygroup not involved in the peptide bound) , such as compound D, show a considerable activity on the enzymatic synthesis of Nitrogen oxide (NO) , by activating macrophages towards its production.
- NO Nitrogen oxide
- the activity on NO synthesis is important for antimicrobic activity of phagocytes, and furthermore for other biologic activity promoted by NO, such as smooth muscle relaxation, immune system regulation, neurotransmission, platelet inhibition and penis erection ("Biochemistry of Nitric oxide and its Redox - Activated forms", J.S. Stamler et al., Science, Vol.258, 18 December 1992) .
- the compounds of the invention having a residue of arginine at the C-terminal end, such as compound D find therapeutic applications in the treatment of diseases of the nervous system and immune system, more specifically in tumor immunotherapy, autoimmune diseases, diseases linked with neurotransmission disturbances and vascular diseases.
- oligopeptides of the invention are synthesized according to the solid phase method, utilizing a semiautomatic synthesizer or manually by using a syringe.
- the solid phase method comprises condensing an aminoacid on a suitably functionalized insoluble polymer, followed by assembling the remaining aminoacids in the successive steps. All the aminoacids are utilized after suitably protecting the ⁇ - a inogroup.
- the other functional groups optionally present in the side chain of the amino acid are suitably protected with acetyl (Ac) , benzyl (Bz), formyl (For), terbutyloxycarbonyl (Boc) , Tosyl (Tos) or 4-methyloxy-2,3,6 trimethylbenzenesulfonyl (Mtr) groups.
- the condensation of the first amino acid on to the polymer occurs by reacting its carboxy group with the polymer functional groups.
- the other aminoacids are assembled by forming an ⁇ -amide bond between their ⁇ -carboxy group and the ⁇ -amino group of the aminoacid linked to the polymer.
- the formation of the ⁇ -amide bond may be accomplished in different ways, for example the carboxy group of the aminoacid to be assembled can be activated by forming a mixed anhydride or an activated ester, according to methods commonly known in the field of peptide synthesis.
- the present invention further relates to a process for preparing the present derivatives, comprising the following steps : a) condensing on a resin the first aminoacid protected at the ⁇ - amino group with P ⁇ , wherein P- ⁇ is a protecting group of the ⁇ - amino group selected from the group consisting of terbutoxycarbonyl (Boc) and fluorenylmethyloxycarbonyl (Fmoc) , by treating a resin with chloromethyl groups with the Cesium salt of the above mentioned protected first aminoacid, in a polar aprotic solvent at a temperature comprised between +40 and +90°C, preferably between +60° and +70°C; or by treating a resin with p- methylbenzhydrylamino groups with the above first aminoacid protected at the ⁇ -amino group, after treating it with a compound P 2 0H known for the activation of the aminoacid ⁇ -carboxy group,
- Step d) Boc and Fmoc groups, both in ⁇ -aminic position and, if any, in lateral chain, are removed before cleaving the peptide from the resin.
- the first protected aminoacid is P 1 -Glu(NHAd)-OH, and P- ⁇ is preferably Boc.
- the first aminoacid derivative is P ⁇ - Arg-(Mtr)-OH, wherein Mtr is 4-methoxy-2,3,6 trimethylbenzenesulfonyl and P- ⁇ is preferably Fmoc.
- the functional groups in the side chain of arginine are protected for example with tosyl (Tos) or with 4- methoxy-2,3,6 trimethylbenzensulfonyl (Mtr); those of Lysine with terbutoxycarbonyl (Boc) or with fluorenylmethyloxycarbonyl
- a resin in the chloromethyl form such as the Merrifield C—R)'resin is preferably used for the compounds A, B and C, while a p-methylbenzhydrylamino resin is preferably used for compound D.
- the p-methylbenzhydrylamino resin is suitable for the preparation of peptides in the form of ⁇ -C0NH2 amides at the ⁇ -C terminal end (such as compound D) , resulting from the acidic cleavage.
- the p-methylbenzhydrylamino resin commercially available in HC1 form, is neutralized, before carrying out step (a).
- the organic solvents can be halohydrocarbons such as dichloromethane and chloroform, ethereal solvents, such as ethylether and tetrahydrofuran and the polar aprotic solvents such as dimethylformamide, dimethylsulfoxide, dioxane, or a mixture thereof.
- dimethylformamide is preferably used as the solvent in step (a) and in step (c) the organic solvent preferably consists of a mixture dichloromethane:dimethylformamide 4:1 (volumetric ratio).
- dimethylformamide is preferably used in steps a) and c) and to wash the functionalized resin.
- the above mentioned cesium salt may be obtained by treating the first aminoacid, protected with P- ⁇ , with cesium carbonate, at room temperature and in a hydroalcoholic environment, preferably in a mixture water-methanol, evaporating then the solvent to dryness, preferably under vacuum.
- the cleavage of the Boc groups is preferably accomplished with solutions of trifluoroacetic acid (TFA) in a halohydrocarbon solvent, such as dichloromethane, having a TFA concentration ranging from 40 to ⁇ 0% (weight/volume or volume/volume) , at temperatures of +20°C - +30 ° C.
- TFA trifluoroacetic acid
- the tertiary amine used for neutralizing trifluoroacetic acid is preferably ethyldiisopropylamine.
- the saturated heterocyclic amine used for the Fmoc cleavage is preferably piperidine, in dimethylformamide, at +20° - +30°C.
- the Tos and Mtr groups can be cleaved in strongly acidic conditions, for instance with trifluoromethanesulphonic acid, or with other known methods .
- P2-OH compounds are selected among those normally used in the peptide synthesis for the formation of active esters , thus activating the ⁇ -carboxy group towards the formation of the peptide bond.
- P2-OH can be for example N-idroxybenzotriazole ( OHBt ) , or a substituted phenol , as for example pentafluorophenol (PfpOH) , p- nitrophenol or 2 , 4-dinitrophenol , and preferably is N- hydroxybenzotriazole .
- the condensing agent can be a dialkylcarbodiimide , such as dicyclohexylcarbodiimide or diisopropylcarbodiimide , preferably disopopyl carbodimide .
- the scavanger can be thioanisole or p-thiocresol or a mixture thereof , and preferably a mixture of these thioderivatives is used .
- oligopeptides obtained according to the present invention are recovered after HF cleavage by evaporation at laboratory temperature under reduced pressure (by means of a common water pump) , followed by extraction with an acetic acid aqueous solution. Once the oligopeptides are recovered, they can be purified by chromatography, utilizing for example a SephadexS ⁇ G 10 (dextrane by gel filtration) column and 0.1 M acetic acid as the eluant. Oligopeptide D is purified on a Bioge ( lS / P2 column.
- Oligopeptide D may be further purified by inverse phase preparative HPLC (by using for example a Vydacs- Cl ⁇ column) .
- the oligopeptides of the invention can be obtained in solid form by lyophilizing the solutions coming from step (e) or from chromatographic purification.
- the lyophilization is carried out by following conventionally known techniques.
- Boc-Glu-OBz that is N-t-Boc-L-Glutamic acid ⁇ -Benzyl ester
- the present invention further relates to therapeutical composition
- therapeutical composition comprising as the active principle a therapeutically effective amount of at least one oligopeptide according to the present invention, or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients.
- compositions are useful in human therapy, in particular for the treatment of the above cited diseases.
- compositions of the present invention may also contain other active principles having a complementary or in any case useful activity.
- compositions are those containing , in association with the oligopeptides of the invention , one or more therapeutically active substances , whose activi ty is enhanced by them , and in particular antigenic substances .
- the therapeutic compositions may be administered to patients by various routes , for example by the oral and the parenteral ones .
- compositions of the invention may be realized according to the known techniques , such as those described for example in
- compositions of the invention are administered on average once or twice a day, anyway they may be more frequently administered, at least in some cases, depending on the patient's conditions and the administration type.
- this active principle is formulated in the form of solid or liquid preparations, such as capsules, tablets, pills, powders, solutions, suspensions, emulsions, optionally in controlled release forms.
- the unitary solid dose may be a soft or hard jelly capsule, containing lubricating agents and inert excipients such as lactose, saccharose and starch.
- the compounds of the present invention may be formulated as well in the form tablets utilizing the conventional excipients such as lactose, saccharose, starch, jelly, alginic acid , stearic acid, magnesium stearate.
- the compounds of the present invention may be administered in injectable formulations, particularly they are dissolved or suspended in pharmacologically acceptable diluents, with a vehicle, being a sterile vehicle such as water or an oil, in the presence or in the absence of other components.
- oils to be used are of animal, vegetable, or synthetic origin, such as peanuts oil, soybean oil and mineral oil.
- vehicle for the injectable solutions water, mineral salts aqueous solutions, dextrose or other sugars aqueous solutions , ethanol , glycols such as propylen- or polyethylen- glycol, may be used.
- Peptides A, B, C were prepared by using a semi automatic synthesizer built in laboratory, or manually in a polypropylene syringe on a chloromethyl Merrifield* ⁇ resin, 1% DVB crosslinking (substitution 1.03 mmoles Cl/g) .
- a p-methylbenzhydrylaminic resin (MBH-resin) (substitution 0.5 mmoles/g) was used for the preparation of peptide D.
- TLC Thin layer chromatography
- TMD tetramethyl-4'-diaminodiphenylmethane
- Mass spectra are carried out on a ZAB-EQ mass spectrometer.
- the FAB ionization technique is executed at 8 kV (Xe) in a thioglycerin : glycerin 3 : 1 matrix.
- the aminoacids analysis is carried out by using a Durrum analyser.
- the analysis samples are hydrolyzed for 24 hours in M
- Boc-Glu(NHAd)-OH 600 mg Boc-Glu(NHAd)-OH are dissolved in a mixture of 10 ml water and 4 ml methanol.
- the carboxylic group titration is accomplished by using a 105. cesium carbonate solution (pH 7 ⁇ ) .
- the Cesium salt of Boc-Glu(NHAd) -OH is obtained which, utilized in excess of 1.1 equivalents with respect to the chloromethyl resin Merrifielc , is dissolved in 10 ml DMF. 1.4 g of the above mentioned resin are added to the DMF solution and the so obtained suspension is maintained under stirring at 6 ° C for 3 days. Then the polymer is removed by filtration and washed with DMF, water, methanol and ether. 1.64 g of esterified resin are obtained. The picric acid test reveals a substitution degree of 0.46 mmoles/g. A, B and C peptides assembly occurs on the Boc-Glu(NHAd)-resin, according to the general scheme hereinbelow reported:
- Peptide D is synthesized starting from Fmoc aminoacid derivatives, utilizing the continuous flux method.
- Fmoc-Arg(Mtr)-0H, as the C-terminal aminoacid is linked to the
- the first assembly step of the peptide in this special case is the neutralization of the commercially available resin in HC1 form.
- the only solvent utilized for washing and condensing is DMF.
- the cleavage of the Fmoc protecting group is carried out in a 20% piperidine solution in DMF for 20 min.
- Raw A, B and C peptides are purified on a Sephadex* ⁇ G 10 column (50 x 1.5 cm) utilizing 0.1 M acetic acid as the eluant.
- Peptide D is purified on a Biogel ( ⁇ R)P2 column (21 x 2.7 cm).
- Aminoacid derivatives amount : Boc-Glu(NHAd)-0H 117 mg
- the yield in peptidyl-resin is 365 mg; 80 mg of raw peptide are obtained; after purification on Sephadex ⁇ G 10 column, 31 mg of purified peptide are obtained.
- Aminoacid derivatives amount : Boc-Glu(NHAd)-0H 117 mg
- the yield in peptidyl-resin is 3 3 mg, 57 mg of raw peptide are obtained; after purification on Sephadex ⁇ G 10 column, 37 mg of purified peptide are obtained.
- Aminoacid derivatives amount : Fmoc-Glu(NHAd)-OH 502 mg
- the yield in peptidyl-resin is 2.1 g; 280 mg of peptide are obtained after purification on a Sephadex G10 column. This product is subjected to a preparative HPLC on a Vydac&'Cl ⁇ column
- FBS fetal calf serum
- RPMI -RPMI 1640 Culture medium (Roswell Park Memorial
- oligopeptides A, B, C and D which were added to the mixture in the amount of 100 ⁇ g, is compared with that of
- Ovoalbumine (dose) Ovoalbumine (dose)
- Balb-c mice were divided in groups, each group of 4 animals, and utilized as splenocytes donors. Each group is treated by subcutaneous route with 100 ⁇ g of one compound selected from oligopeptides A, B or C or 1-aminoadamantane (AmAd) on days -2, -1 and 0 before the induction of the regional GVHR. A control group is not treated with any of the above mentioned substances.
- a suspension of aggregated spleen cells obtained from the donors is prepared by passing the cut spleens in a RPMI 1640 medium through a fine sieve. After centrifugation (800 x g, 8 min.), the spherical mass obtained is resuspended in RPMI 1640 up to obtaining the final o density of 1 x 10 /ml (only nucleated cells).
- TEST 3 - Hemoagglutination Sheep red blood cells (SRBC) are administered by intraperitoneal route to different mice groups in an amount of 5 x 10' in 0.50 ml
- Titres are expressed as log 2 of the highest serum dilution still showing agglutination.
- Table 3 Total hemoagglutination titre after primary immunization with sheep red blood cells (SRBC) .
- Compound B is the most active, inducing a significant increase in total hemoagglutination titre.
- TEST 4 - Response of plaque forming cells 100 ⁇ g oligopeptides A, B and C and 1-amino adamantane (AmAD) are administered together with SRBC by subcutaneous route to different mice groups immunized with SRBC (5 x 10' per animal, administered by intraperitoneal route) . The control group has not received the substances to be tested. A single cell splenocytes suspension (2 x 10 /ml) is obtained on the 5 day after immunization.
- PFC plaque forming cells
- 0.2 ml of said suspension are mixed with an equal SRBC volume (1 x 10-Vml) and with guinea-pig complement (diluted 1 : 10).
- Every component is prepared in the RPMI 1640 medium.
- the mixture is maintained in Cunningham chambers (0.1 ml) for 1 hour at 37 °C and at 100% relative humidity.
- the number antibody-producing B-cells is evaluated as the PFC number per 10 splenocytes.
- B is the only active compound in this test.
- splenic cells are obtained from donors mice treated subcutaneously with 100 ⁇ g of the substances to be tested by passing their spleens cut in a RPMI 1640 medium through a fine sieve.
- the obtained splenic cells (0.2 ml per well with a density of 2.5 x 10 /ml) are cultured for 72 hours in FB** 96-wells microplates in the complete RPMI 1640 medium (10% FBS, 0.005% gentamicine) , at 37°C, with 5% C0 2 and 100% relative humidity, both in the absence or in the presence of mitogens CON A (concanavalin A)(l ⁇ g/ml) and LPS (lipopolysaccharide) (LPS S.typhy murium, Sigma ⁇ (20 ⁇ g/ml). During the last 6 hours of culture, cells are collected and their radioactivity is determined by using a scintillation beta- counter.
- CON A concanavalin A
- LPS lipopolysaccharide
- All the tested oligopeptides are active in promoting splenocytes proliferation.
- Compound B is the most active also in increasing the mitogenic answer to LPS. Because LPS is considered to be a specific mitogen for B-cells and CON A for T-cells, the test shows an action specificity of the tested compounds versus B and T cells.
- the pyrogenic effect of the above mentioned derivatives A, B, C and D is determined on rabbits having a weight of from 2 to 2.3 kg.
- the compounds are injected by intravenous route and the effect is compared with that obtained with muramyl dipeptide
- MDP a very powerful pyrogenic adjuvant. Temperature is measured by a rectal thermistor thermometer every hour.
- Results are shown in Table 6. The reported values are the average of values obtained from groups of 5 animals.
- Compound B proves to be the most active in the stimulation of the humoral activity in both TESTS 3 and 4.
- mice C 57 Bl/6 (Charles River) female mice were used, weighing on average 20 g.
- Compound D was dissolved in physiological solution and intraperitoneally (i.p.) administered at the dose of 15 mg/kg to groups of at least 10 mice, by following different protocols of treatment.
- the groups of treated animals the day in which they received the specific treatment, and the received treatment protocol (the day 0 is that in which the tumoral cells transplant was conducted; the day -3 corresponds to 3 days before this transplant and +3 means 3 days after the same) .
- Group 1 (control) day -3 physiological solution day 0 : physiological solution + tumoral cells day +3 : physiological solution
- Group 2 (3x peptide D) day -3 peptide D day 0 peptide D + tumoral cells day +3 peptide D
- Table 8 reports in particular the data on tumor weight, obtained by administering Compound D three times (3x) (Group 2), in comparison with the control group (Group 1).
- the results relating to lung metastases formation are the most important, since they show that Compound D is able to significantly reduce metastases incidence at lung level, some animals being free of metastases.
- the data of Table 9 concern in particular the metastases number observed in mice treated three times with Compound D (Group 2) in comparison with the control group (Group 1)
- Group 1 (control) Group 2 (3x compound D) mice No. mice % mice No. mice % large 10 83-3 3 27.3 small 2 16.7 8 72.7 chi-square 9-8 P ⁇ 0.01
- Group 1 (control) Group 2 (3x compound D) mice No. mice % mice No. mice % large 10 83-3 4 36.4 small 2 16.7 7 63.6 chi-square 3-8 P ⁇ 0.05
- Group 1 (control) Group 2 (3x compound D) mice No. mice % mice No. mice % large 12 100 9 81.8 small 0 0 2 18.2 chi-square 6.2 P ⁇ 0.05 Notes :
- Group 2 consists of 11 mice. TABLE 9 Number of lung metastases after compound D administration (15 mg/kg; three times; on days: -3, 0.+3)
- Group 1 Group 2 (control) (3x compound D) No. of metastases No. of metastases Treated animals
- mice of inbred strain Balb/c were used.
- LPS Lipopolysaccharide
- LPS is a substance known for its ability to activate N0- synthetase enzyme and therefore to activate NO production.
- the control Group was made of 12 animals, divided in 2 sub-groups of 6 animals each.
- Sub-group 1 was injected with saline, then macrophages culture.
- Sub-group 2 was injected with saline, then macrophages culture in presence of LPS 5 U-
- the Treated Group was made of 12 animals, divided in 2 sub-groups of 6 animals each.
- Sub-group 3 Compound D 200 ⁇ g (-Id), then macrophages culture.
- Sub-group 4 Compound D 200 ⁇ g (-Id), then macrophages culture in presence of LPS 5 P- Macrophages culture conditions:
- Peritoneal macrophages were isolated and cultivated in Nunc 96- well FB-microplates in RPMI-1640 medium (10% FBS, 0.005% Gentamycin, 0.05 ⁇ M 2-Mercaptoethanol) under the following conditions: 37°C, 5% C0 2 , 100% relative humidity, 24 hours.
- Griess reagent was used to determine spectrophotometrically nitrite levels, carrying out the detection at 5 ⁇ nm with an Uniscan II reader. The obtained results are reported in Table 10 here below:
- Nitrogen Oxide (NO) production is expressed as nitrites amount, which is in turn expressed as optical density at 540 nm (OD 540 nm) .
- - Average (AVG) is calculated on the results obtained on 6 animals.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to oligopeptide derivatives of leukokinin fragments, containing at least one residue deriving from 1-amino-adamantane, having immunostimulating, immunoadjuvant and antiviral activity, a process for their preparation, and therapeutical compositions containing them as the active principles.
Description
IMMUNO MODULATING PEPTIDE DERIVATIVES OF LEUKOKININ FRAGMENTS.
FIELD OF THE INVENTION
The present invention relates to oligopeptide derivatives of leukokinin fragments, having immunomodulating activity, a process for their preparation and pharmaceutical compositions containing them.
PRIOR ART DISCLOSURE
Immunomodulating agents are substances able to act on the organism natural defence, either by stimulating the immune system in case this is depressed, or by inhibiting same if it is hyperexcited.
Some of these compounds found a therapeutical application, for example in the immunotherapy of tumours and in the treatment of recurrent infections and allergic diseases. In particular these substances are defined as immunostimulants when showing a prevailingly stimulating action and as immunoadjuvants when they are able to enhance antigens immunostimulating action.
Immunoadjuvants can be advantageously used in the field of vaccines, if administered in association with the antigens which form the same vaccines.
As the result of an intensive research carried out during the course of the last twenty years, several compounds have been identified, characterized by showing immunomodulating activity, comprising in their molecular structure, peptides, glycopeptides
or lipopeptides.
Most of these compounds have not been clinically tested, whereas other compounds did not prove sufficiently active when clinically experimented. Some of them gave serious side-effects, other compounds showed too short half-lives or a very wide non specific activity pattern, that it resulted very difficult to use them for long time periods. Particularly, among the compounds having immunomodulating activity we mention muramyl dipeptide (MDP) or N-acetylmuramyl-L- alanyl-D-isoglutamine, a product of bacterial origin which shows pyrogenic activity, and its correlated compounds, called muramyl or desmuramyl peptides because of the presence or the absence in their structure of muramic acid residue, respectively. In particular it was found that some derivatives free from this residue maintain immunoadjuvant and immunomodulating activity, and that the insertion of lipophylic residues both in muramyl and in desmuramyl peptides brought to a biologic activity increase. (Adam A., Synthetic adjuvants, Modern Concepts in Immunology. Ed. C.A. Bona, J. Wiley and Sons, Inc. N.Y. pp 10-17, 1 85).
In addition, it is known that the effect of several immunostimulants having peptidic origin may be increased when they are administered in combination with mineral oils or if they are incorporated in liposome type structures (Masek K. et al., Experientia, 3**, 1363. 1978).
On the base of the preceding research with muramyl peptides having bacterial origin, more than ten years ago Masek and co- workers were able to identify an other compound having immunostimulating and immunoadjuvant activity, where the muramyl dipeptide essential molecule, namely L-alanine-D-isoglutamine , was linked to 1 - amino- admantane.
The resulting compound, known as adamantyl dipeptide (AdDp) , proved to possess also rather considerable antiviral activity (Masek K. et al . , The immunomodulatory property of a novel synthetic compound, adamantyl amide-dipetide, Meth. Find. Exptl.
Clin. Pharmacol. 6, 667, 1984; Masek K. , Immunopharmacological Properties of Synthetic Muramyl Peptides and Their Analogs, in: Advances in the Bioscience 68, Immunomodulators and Nonspecific Host Defence Mechanism, against Microbial Infections, Eds. K.N. Masihi and W. Lange, Pergamon Press, pages 11-19, 1988).
It is known that tetrapeptides derived from fragments 289- 92 of long chain leukokinins increase the macrophages phagocytosis activity as well as the cytolytic activity of granulocytes and T cells, stimulating through these and probably other activities both the humoral and the cell-mediated immunity (V.A. Na jar and K. Nishioka, Nature 228,672, 1970; V.A. Najjar et al.. The Chemistry and Biology of Tuftsin in: Lymphokines Reports , Vol.l, PP 157-179. academic Press, N.Y., I98O ; K. Nishioka et al., Biochim. Biophys. Acta 310, 230, 1973). The presence of adamantane residue in oligopeptides imparts these
compounds advantageous pharmacokinetic properties (Walder P.et al., Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP) , a muramyl dipeptide derivative in mice. Immunopharm, and Immunotoxicol . 13, PP 101-119, 1991) and in particular it improves the transfer of oligopeptides to various organs and immuno competent cells (Tsuzuki N. et al., Adamantane as a brain directed drug carrier for poorly adsorbed drug : antinociceptive effects of (D-ala ) Leu-Enkephalin derivatives conjugated with 1 -adamantane moiety, Biochem. Pharmacol.41, R5-R8, 1991 ) •
The need is felt to find new and very active compounds, which are well tolerated by organism and have a high immunostimulating and immunoadjuvant activity. DETAILED DESCRIPTION The Applicant has now unexpectedly found a new type of immunomodulating and immunoad uvant compounds, where the hydrophobic and metabolically stable structure of adamantane is linked to endogenous leukokinin fragments. In particular, the derivatives of the present invention are oligopeptide derivatives of endogenous leukokinin fragments, containing at least one residue L-Glu(NH-Ad) , and their pharmaceutically acceptable salts.
As the salts we mean those obtained by salification with acids or with bases both of organic or inorganic type. The residue L-Glu(NHAd) is L-glutamic acid gamma- (1-
adamantylamide) ; Ad indicates the hydrocarbon residue present in
1- amino- adamantane (Ad-NI^) •
In the present description the peptides nomenclature used was that recommended in "Nomenclature and Symbols for aminoacids and peptides" , Eur. J . Biochem. 138, 9 (1984) .
The symbols relating to aminoacids denote, where not differently indicated, the L configuration of the carbon atom bringing the α- aminic group .
Endogenous leukokinin are peptides of natural origin present in eukaryotic cells , for example of mammals .
In particular, as the oligopeptide derivatives of leukokinin fragments we mean in the instant description oligopeptides consisting of aminoacids present in endogenous leukokinin fragments . More in particular , the present derivatives consist of oligopeptides having aminoacids in common with endogenous leukokinin fragments , in which one or more , preferably from 1 to
3 , L-Glu(NHAd) residues , replace or alternate the aminoacids residues of these fragments . Examples of leukokinin fragments are 282-292 residue , also known as tuftsin (Thr-Lys-Pro-Arg) , 245-248 residue (Pro-Lys-Pro-Lys ) and 341-344 residue (Gly-Gln-Pro-Arg) .
The aminoacid residues number in the present oligopeptides ranges from 2 to 10, preferably from 4 to 5 - The oligopeptides of the invention are completely different from
MDP and AdDP immunomodulators, because they contain a peptidic portion of animal (mammal in particular) , rather than bacterial origin.
The Applicant has found that the oligopeptides of the invention are highly active "in vivo", in particular in stimulating the cellular and humoral immune reaction, and have a strong antiviral activity.
Moreover, the present oligopeptides have a low toxicity, rendering them well tolerated by the organism, and in particular they are not pyrogen.
The oligopeptides of the invention are useful in the human therapy, both alone and in combination with other therapeutically active substances; for example, because of their remarkable immunomodulating, in particular immunostimulating and immunoadjuvant properties, they find application in the treatment and in the prophylaxis of diseases associated with a deficiency of the immuno response, as for example tumors and infections of various origin, for example of bacterial or viral origin, and in recurrent infections. The association with other therapeutically active substances concerns any kind of therapeutically suitable association, but preferably the association with substances whose activity is increased by the present oligopeptides, for example with substances having antigenic properties. The compounds of the present invention are therefore useful adjuvants in vaccines.
Among the preferred derivatives of the present invention, we mention peptides characterized by containing in the aminoacid sequence from 1 to 2 L-Glu(NHAd) residues, at least a Lys residue and at least a residue selected from the group consisting of Arg, Pro and Pro-Arg.
More preferred derivatives are the following: H-Lys-Glu(NH-Ad)-Pro-Arg-Glu(NH-Ad)-OH (A) H-Lys-Glu(NH-Ad)-Arg-Glu(NH-Ad)-OH (B) H-Lys-Glu(NH-Ad)-Pro-Glu(NH-Ad)-OH (C) H-Glu(NH-Ad)-Lys-Pro-Arg-NH2 (D)
The presence of a hydrophobic residue derived from 1- aminoadamantane not only improves the oligopeptides transfer through the biological membranes and affects oligopeptides flexibility and conformation , but it also improves the bond between immunocompetent cells and cellular membranes , bringing, as a result, to a favourable pharmacokinetic profile. If compared to the known compounds , the present oligopeptides exhibit a more specific activity on the humoral immunity (see for example the compound B ) or on the cellular one ( see the compounds C and D) .
Further, the compounds of the invention have the advantage to be apyrogenic , more stable at the metabolism, and to exhibit a favourable pharmacokinetic profile . The Applicant has furthermore found that the oligopeptides of the present invention having an arginine residue at the C-terminal
end (the one bearing an α-carboxygroup not involved in the peptide bound) , such as compound D, show a considerable activity on the enzymatic synthesis of Nitrogen oxide (NO) , by activating macrophages towards its production. The activity on NO synthesis is important for antimicrobic activity of phagocytes, and furthermore for other biologic activity promoted by NO, such as smooth muscle relaxation, immune system regulation, neurotransmission, platelet inhibition and penis erection ("Biochemistry of Nitric oxide and its Redox - Activated forms", J.S. Stamler et al., Science, Vol.258, 18 December 1992) .
The compounds of the invention having a residue of arginine at the C-terminal end, such as compound D, find therapeutic applications in the treatment of diseases of the nervous system and immune system, more specifically in tumor immunotherapy, autoimmune diseases, diseases linked with neurotransmission disturbances and vascular diseases.
The oligopeptides of the invention are synthesized according to the solid phase method, utilizing a semiautomatic synthesizer or manually by using a syringe.
The solid phase method comprises condensing an aminoacid on a suitably functionalized insoluble polymer, followed by assembling the remaining aminoacids in the successive steps. All the aminoacids are utilized after suitably protecting the α- a inogroup.
The other functional groups optionally present in the side chain of the amino acid are suitably protected with acetyl (Ac) , benzyl (Bz), formyl (For), terbutyloxycarbonyl (Boc) , Tosyl (Tos) or 4-methyloxy-2,3,6 trimethylbenzenesulfonyl (Mtr) groups. The condensation of the first amino acid on to the polymer occurs by reacting its carboxy group with the polymer functional groups. After removing the protecting group of the α-amino group of the aminoacid supported on the polymer, the other aminoacids are assembled by forming an α-amide bond between their α-carboxy group and the α-amino group of the aminoacid linked to the polymer.
The formation of the α-amide bond may be accomplished in different ways, for example the carboxy group of the aminoacid to be assembled can be activated by forming a mixed anhydride or an activated ester, according to methods commonly known in the field of peptide synthesis.
At the end of the synthesis, the protecting groups are removed by using suitable techniques. The present invention further relates to a process for preparing the present derivatives, comprising the following steps : a) condensing on a resin the first aminoacid protected at the α- amino group with P^, wherein P-^ is a protecting group of the α- amino group selected from the group consisting of terbutoxycarbonyl (Boc) and fluorenylmethyloxycarbonyl (Fmoc) , by treating a resin with chloromethyl groups with the Cesium salt
of the above mentioned protected first aminoacid, in a polar aprotic solvent at a temperature comprised between +40 and +90°C, preferably between +60° and +70°C; or by treating a resin with p- methylbenzhydrylamino groups with the above first aminoacid protected at the α-amino group, after treating it with a compound P20H known for the activation of the aminoacid α-carboxy group, in the presence of a dialkylcarbodiimide, at room temperature (about +20°C - +30°C) ; b) removing the above mentioned protecting group Pi from the amino acid supported on the resin obtained in a) , by treatment, when P^ is Boc, with trifluoroacetic acid, at a temperature comprised between 0 and +50°C, preferably between +20βC and +30°C, followed by neutralization with a base (an alyphatic tertiary amine substituted with C^-Cg alkyl groups) , and when P^ is Fmoc, with a solution of a saturated heterocyclic amine in an organic solvent; c) assembling onto the resin the next aminoacid protected at the alpha-aminogroup with P^ , where P-^ is above defined, in an organic solvent at a temperature comprised between 0 and +50°C, preferably between +20°C and +30°C, after treating said successive aminoacid with P2OH, where P2OH is a hydroxy compound known for the activation of the aminoacid carboxy group, in the presence of a condensing agent, at a temperature comprised between 0 and +50°C, preferably between +20°C and +30°C; d) removing as in step b) the protecting group P^ and the other
Boc or Fmoc groups possibly present in the lateral chain of the peptide supported on the resin obtained in step c) ; e) cleaving the final oligopeptide from the polymeric support by means of treatment with liquid HF, at a temperature between -20° and 0°C, in the presence of a "scavenger", followed by the recovery of the thus obtained oligopeptide.
Under preferred conditions from 1 to 1.2 equivalents of cesium salt, 2 equivalents of the successive aminoacid, 2 equivalents of P2OH and 2 equivalents of condensing agent are used in respect of the amount of resin used in step a) .
In the present description the equivalents refer to the amount of resin initially used in step (a).
After each step the functionalized resin is washed with organic solvents as encompassed in the solid phase technique. Steps b) and c) are repeated for the necessary number of times and aminoacids to complete the desired peptide sequence. During step d) , Boc and Fmoc groups, both in α-aminic position and, if any, in lateral chain, are removed before cleaving the peptide from the resin. in case of the oligopeptides A, B and C the first protected aminoacid is P1-Glu(NHAd)-OH, and P-^ is preferably Boc. In case of oligopeptide D, the first aminoacid derivative is P^- Arg-(Mtr)-OH, wherein Mtr is 4-methoxy-2,3,6 trimethylbenzenesulfonyl and P-^ is preferably Fmoc. in the present process the functional groups in the side chain of
arginine are protected for example with tosyl (Tos) or with 4- methoxy-2,3,6 trimethylbenzensulfonyl (Mtr); those of Lysine with terbutoxycarbonyl (Boc) or with fluorenylmethyloxycarbonyl
(Fmoc) . The protected aminoacid preferably used are:
Boc-Glu(NHAd)-OH (oligopeptides A, B and C)
Boc-Arg(Tos)-OH (oligopeptides A, B and C)
Fmoc-Lys(Fmoc)-OH (oligopeptides A, B and C)
Boc-Pro-OH (oligopeptides A, B and C) ; Fmoc-Glu(NHAd)-0H (oligopeptide D)
Fmoc-Arg(Mtr)-0H (oligopeptide D)
Fmoc-Lys(Boc)-0H (oligopeptide D)
Fmoc-Pro-OH (oligopeptide D) .
In the present process a resin in the chloromethyl form such as the Merrifield C—R)'resin is preferably used for the compounds A, B and C, while a p-methylbenzhydrylamino resin is preferably used for compound D.
The p-methylbenzhydrylamino resin is suitable for the preparation of peptides in the form of α-C0NH2 amides at the α-C terminal end (such as compound D) , resulting from the acidic cleavage.
For the preparation of compound D, the p-methylbenzhydrylamino resin, commercially available in HC1 form, is neutralized, before carrying out step (a). The organic solvents can be halohydrocarbons such as dichloromethane and chloroform, ethereal solvents, such as ethylether and tetrahydrofuran and the polar
aprotic solvents such as dimethylformamide, dimethylsulfoxide, dioxane, or a mixture thereof.
In the preparation of compounds A, B, and C, dimethylformamide is preferably used as the solvent in step (a) and in step (c) the organic solvent preferably consists of a mixture dichloromethane:dimethylformamide 4:1 (volumetric ratio).
In the synthesis of derivative D, dimethylformamide is preferably used in steps a) and c) and to wash the functionalized resin.
The above mentioned cesium salt may be obtained by treating the first aminoacid, protected with P-^, with cesium carbonate, at room temperature and in a hydroalcoholic environment, preferably in a mixture water-methanol, evaporating then the solvent to dryness, preferably under vacuum.
The cleavage of the Boc groups is preferably accomplished with solutions of trifluoroacetic acid (TFA) in a halohydrocarbon solvent, such as dichloromethane, having a TFA concentration ranging from 40 to β0% (weight/volume or volume/volume) , at temperatures of +20°C - +30°C.
The tertiary amine used for neutralizing trifluoroacetic acid is preferably ethyldiisopropylamine.
The saturated heterocyclic amine used for the Fmoc cleavage is preferably piperidine, in dimethylformamide, at +20° - +30°C.
The Tos and Mtr groups, possibly present on the guanidine group of the arginine residue, can be cleaved in strongly acidic conditions, for instance with trifluoromethanesulphonic acid, or
with other known methods .
Referring to P2-OH compounds , they are selected among those normally used in the peptide synthesis for the formation of active esters , thus activating the α-carboxy group towards the formation of the peptide bond.
P2-OH can be for example N-idroxybenzotriazole ( OHBt ) , or a substituted phenol , as for example pentafluorophenol (PfpOH) , p- nitrophenol or 2 , 4-dinitrophenol , and preferably is N- hydroxybenzotriazole . The condensing agent can be a dialkylcarbodiimide , such as dicyclohexylcarbodiimide or diisopropylcarbodiimide , preferably disopopyl carbodimide .
The scavanger can be thioanisole or p-thiocresol or a mixture thereof , and preferably a mixture of these thioderivatives is used .
In the presence of this mixture the remotion of the oligopeptide from the polymeric matrix is accelerated and proceeds substantially in the absence of undesired side reactions. The oligopeptides obtained according to the present invention are recovered after HF cleavage by evaporation at laboratory temperature under reduced pressure (by means of a common water pump) , followed by extraction with an acetic acid aqueous solution. Once the oligopeptides are recovered, they can be purified by chromatography, utilizing for example a SephadexS^G 10 (dextrane
by gel filtration) column and 0.1 M acetic acid as the eluant. Oligopeptide D is purified on a Bioge(lS/P2 column. Oligopeptide D may be further purified by inverse phase preparative HPLC (by using for example a Vydacs- Clδ column) . The oligopeptides of the invention can be obtained in solid form by lyophilizing the solutions coming from step (e) or from chromatographic purification.
The lyophilization is carried out by following conventionally known techniques. The compound P1~Glu(NHAd) -OH can be prepared starting from glutamic acid in the protected form as compound,
wherein P^ has the above mentioned meaning and is preferably Boc, P2 is the residue of the above mentioned compound P2OH (for example P2 = Pfp, namely the aromatic residue penta-fluorophenyl) and P is a protecting group of the carboxy group, for example the benzyl group. Pi-Glu(0P2)0Po can be prepared condensing the diprotected aminoacid P^-Glu-OP , for instance Boc-Glu-OBz (that is N-t-Boc-L-Glutamic acid α-Benzyl ester) , with P2θH=pentafluorophenol in the presence of a diakylcarbodiimide then it is converted into the corresponding j"7adamantylamide, by treatment with 1-aminoadamantane with methods known to the skilled in the art. Alternatively, P^-Glu-OP (Boc-Glu-OBz) can be reacted with 1-aminoadamantane after treatment with P 0H=N- hydroxybenzotriazole in the presence of a diakylcarbodiimide. P is then removed according to conventional techniques, such as,
for the -OBz group, treatment with H /Pd.
The present invention further relates to therapeutical composition comprising as the active principle a therapeutically effective amount of at least one oligopeptide according to the present invention, or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients.
These compositions are useful in human therapy, in particular for the treatment of the above cited diseases.
Besides the above cited active principle and excipients, the compositions of the present invention may also contain other active principles having a complementary or in any case useful activity.
Particularly preferred therapeutical compositions are those containing , in association with the oligopeptides of the invention , one or more therapeutically active substances , whose activi ty is enhanced by them , and in particular antigenic substances .
In order to obtain the desired effects , the therapeutic compositions may be administered to patients by various routes , for example by the oral and the parenteral ones .
The compositions of the invention may be realized according to the known techniques , such as those described for example in
"Remington ' s pharmaceutical Science handbook" , Hack Publishing
Co . , USA . The compositions of the invention are administered on average
once or twice a day, anyway they may be more frequently administered, at least in some cases, depending on the patient's conditions and the administration type. When orally administered, this active principle is formulated in the form of solid or liquid preparations, such as capsules, tablets, pills, powders, solutions, suspensions, emulsions, optionally in controlled release forms.
The unitary solid dose may be a soft or hard jelly capsule, containing lubricating agents and inert excipients such as lactose, saccharose and starch.
The compounds of the present invention may be formulated as well in the form tablets utilizing the conventional excipients such as lactose, saccharose, starch, jelly, alginic acid , stearic acid, magnesium stearate. When parenterally administered the compounds of the present invention may be administered in injectable formulations, particularly they are dissolved or suspended in pharmacologically acceptable diluents, with a vehicle, being a sterile vehicle such as water or an oil, in the presence or in the absence of other components.
The oils to be used are of animal, vegetable, or synthetic origin, such as peanuts oil, soybean oil and mineral oil. Generally as the vehicle for the injectable solutions, water, mineral salts aqueous solutions, dextrose or other sugars aqueous solutions , ethanol , glycols such as propylen- or polyethylen-
glycol, may be used.
Some examples of the present invention are hereinbelow reported for illustrative, but not limitative purpose.
PEPTIDES A.B.C AND D PREPARATION The following abbreviations are used:
Boc : tert-butyloxycarbonyl
Fmoc : fluorenylmethyloxycarbonyl
Tos : tosyl
Mtr : 4-methoxy-2,3,6-trimethylbenzensulfonyl NH-Ad : 1-adamantylamino
HOBt : N-hydroxybenzotriazole
TFA : trifluoroacetic acid
EDIA : ethyldiisopropylamine
MeOH : methanol DIC : diisopropylcarbodiimide
DCC : dicyclohexyl carbodiimide
DMF : dimethylformamide
Et20 : dimethylether
DCM : dichloromethane MBH : p-methylbenzhydrylamine
Materials and methods
General procedure for the peptide synthesis in solid phase are reported in the following publications :
J.M. Stewart, J.D. Young, Solid Phase Peptide Synthesis, Pierce Chem. Comp., 1984; E. Atherton and R.C. Sheppard, Solid Phase
Peptide Synthesis-Practical Approach, RTL Oxford Press 1989.
Peptides A, B, C were prepared by using a semi automatic synthesizer built in laboratory, or manually in a polypropylene syringe on a chloromethyl Merrifield*^resin, 1% DVB crosslinking (substitution 1.03 mmoles Cl/g) .
A p-methylbenzhydrylaminic resin (MBH-resin) (substitution 0.5 mmoles/g) was used for the preparation of peptide D.
Analytical methods:
Thin layer chromatography (TLC) is carried out on TLC Kieselgel Merclr^-UV-254 plates in ethyl acetate : pyridine : acetic acid : water 5 : 5 : 1 : 3 (SI) system; the products revelation is accomplished with ninhydrin or by the chlorination/TMD method
(TMD = tetramethyl-4'-diaminodiphenylmethane) .
Mass spectra are carried out on a ZAB-EQ mass spectrometer. The FAB ionization technique is executed at 8 kV (Xe) in a thioglycerin : glycerin 3 : 1 matrix.
The aminoacids analysis is carried out by using a Durrum analyser. The analysis samples are hydrolyzed for 24 hours in M
HC1 in the presence of phenol. The following aminoacid derivatives are utilized for the synthesis:
Boc-Glu(NHAd)-OH (oligopeptides A, B and C)
Boc-Arg(Tos)-OH (oligopeptides A, B and C)
Fmoc-Lys(Fmoc)-0H (oligopeptides A, B and C) Boc-Pro-OH (oligopeptides A, B and C);
Fmoc-Glu(NHAd)-OH (oligopeptide D)
Fmoc-Arg(Mtr)-OH (oligopeptide D)
Fmoc-Lys(Boc)-OH (oligopeptide D)
Fmoc-Pro-OH (oligopeptide D) .
All these derivatives, with the exception of Fmoc-Arg(Mtr)-OH
(Bachem^ commercial product) are prepared in our laboratory, using conventional methods known for introducing Boc, Fmoc and Tos groups. Experiments description in the case of A, B and C peptides the first esterification step is carried out following Gisin method (Gisin, B.F., Helv. Chem. Acta 56, 1476-1482, 1973).
600 mg Boc-Glu(NHAd)-OH are dissolved in a mixture of 10 ml water and 4 ml methanol. The carboxylic group titration is accomplished by using a 105. cesium carbonate solution (pH 7 Λ ) .
After evaporation, the Cesium salt of Boc-Glu(NHAd) -OH is obtained which, utilized in excess of 1.1 equivalents with respect to the chloromethyl resin Merrifielc , is dissolved in 10 ml DMF. 1.4 g of the above mentioned resin are added to the DMF solution and the so obtained suspension is maintained under stirring at 6 °C for 3 days. Then the polymer is removed by filtration and washed with DMF, water, methanol and ether. 1.64 g of esterified resin are obtained. The picric acid test reveals a substitution degree of 0.46 mmoles/g.
A, B and C peptides assembly occurs on the Boc-Glu(NHAd)-resin, according to the general scheme hereinbelow reported:
1. Polymer washing in 10 ml DCM 3x2 min.;
2. Cleavage of Boc protecting group Boc remotion in 10 ml 0JU TFA for 30 min. ;
3. polymer washing in 10 ml DCM 3x2 min.;
4. neutralization with a 10 EDIA solution, 2x5 min.;
5. polymer washing in 10 ml DCM 3x min.;
6. condensing the next aminoacid with HOBt active esters prepared in situ, up to a negative response to the blu Bromophenol test
(V. Krchnak et. al., Coll. Czech. Chem. Commun. , 53, 25 3, 1988) and to Kaiser ninhydrin test.
HOBt active esters preparation in situ
The suitably protected aminoacid derivative, (two times in excess with respect to the resin) is dissolved in 10 ml of a DCM : DMF 4
: 1 mixture.
The calculated amounts of HOBt and DIC (2 equivalents) are added and the so obtained mixture is sucked in the syringe containing the polymer-deprotected peptide (prepared as above described) . The peptide-resin suspension is left in the coupling medium under rest or under magnetic stirring for 20/40 minutes.
The condensation reaction completion is evidenced by a negative response to the above mentioned colorimetric tests.
The condensation of the sterically hindered adamantylamide derivatives proceeds more slowly (1 hour) and generally is
repeated twice.
In the last synthesis step both Boc and Fmoc groups are removed.
For removing Fmoc, a 20% piperidine solution in DMF (10 ml) for
20 minutes is used. The final washing is carried out with DMF 3x10 ml, DCM 3x10 ml,
MeOH 3x10 ml and ethyl ether 3 10 ml for about 2 min. for every washing, and in the end, the polymer-peptide is dryed in a dryer.
Peptide D is synthesized starting from Fmoc aminoacid derivatives, utilizing the continuous flux method. Fmoc-Arg(Mtr)-0H, as the C-terminal aminoacid is linked to the
MBH-polymer by means of the HOBt active ester method before described at +20°C - +30°C.
The first assembly step of the peptide in this special case is the neutralization of the commercially available resin in HC1 form.
The general preparation scheme for compound D is analogous to the one previously described for compounds A, B and C, with the exceptions herein below reported.
The only solvent utilized for washing and condensing is DMF. The cleavage of the Fmoc protecting group is carried out in a 20% piperidine solution in DMF for 20 min.
Obviously, in the synthesis of compound D the neutralization step required after the TFA cleavage of Boc protecting groups is omitted. The remotion of A, B, C and D peptides from the polymeric support
is realized in 10 ml liquid HF for 1 hour at -10°C, in the presence of thioanisole (0.2 ml) and p-thiocresole (0.2 ml), utilized as scavengers.
After evaporating the reaction mixture (laboratory temperature, vacuum of a water aspirator) , the obtained solid material is washed with ethyl acetate, the peptides are extracted with a solution of 20% acetic acid in water and separated by lyophilization.
Raw A, B and C peptides are purified on a Sephadex*^G 10 column (50 x 1.5 cm) utilizing 0.1 M acetic acid as the eluant.
Peptide D is purified on a Biogel (βR)P2 column (21 x 2.7 cm).
Purification progress is followed by TLC.
Pure fractions are collected and lyophilized. In addition peptide
D is purified by preparative HPLC. The amount of the utilized polymers and of the aminoacid derivatives, the analytical results and the yields are reported in the description for the individual compounds.
The assigned structures are confirmed by mass spectroscopy (see
Fig. 1-4) and by the aminoacid analyses. Peptide H-Lys-Glu(NH-Ad)-Pro-Arg-Glu(NH-Ad)-OH (A)
Polymer amount : 335 mg
Aminoacid derivatives amount : Boc-Glu(NHAd)-0H 117 mg
Boc-Pro-OH 66 mg
Boc-Arg(Tos)-0H 132 mg Fmoc-Lys(Fmoc)-0H 182 mg
106 mg of raw peptide are obtained from 347 mg of peptidyl-resin and after purification on Sephadex^G 10 column, 61 mg of peptide are obtained.
Mass spectra FAB+ [M+H]+ : 9 5-1. Aminoacids analysis : Glu (2) 2.08; Pro (1) 0-98; Lys (1) 0.92;
Arg (1) 1.02.
TLC in SI system.
Peptide H-Lys-Glu(NH-Ad)-Arg-Glu(NH-Ad)-OH (B)
Polymer amount : 335 mg Aminoacid derivatives amount : Boc-Glu(NHAd)-0H 117 mg
Boc-Arg(Tos)-0H 132 mg Fmoc-Lys(Fmoc)-0H 182 mg
The yield in peptidyl-resin is 365 mg; 80 mg of raw peptide are obtained; after purification on Sephadex^G 10 column, 31 mg of purified peptide are obtained.
Mass spectra FAB+ [M+H]+ : 827.5.
Aminoacids analysis : Glu (2) 2.19; Lys (1) 0.86; Arg (1) 0.94.
TLC in SI system.
Peptide H-Lys-Glu(NH-Ad)-Pro-Glu(NH-Ad)-OH (C) Polymer amount : 335 mg
Aminoacid derivatives amount : Boc-Glu(NHAd)-0H 117 mg
Fmoc-Lys(Fmoc)-0H 182 mg Boc-Pro-OH 66 mg
The yield in peptidyl-resin is 3 3 mg, 57 mg of raw peptide are obtained; after purification on Sephadex^ G 10 column, 37 mg of
purified peptide are obtained.
Mass spectra FAB+ [M+H]+ : 769-0.
Aminoacids analysis : Glu (2) 1.97; Pro (1) 0.88; Lys (1) 1.14.
TLC in SI system.
Peptide H-Glu(NH-Ad)-Lys-Pro-Arg-NH2(D)
MBH-polymer amount : 1600 mg, s=0.5 mmoles/g.
Aminoacid derivatives amount : Fmoc-Glu(NHAd)-OH 502 mg
Fmoc-Ar (Mtr)-OH 610 mg Fmoc-Lys(Boc)-0H 468 mg Fmoc-Pro-OH 337 mg
The yield in peptidyl-resin is 2.1 g; 280 mg of peptide are obtained after purification on a Sephadex G10 column. This product is subjected to a preparative HPLC on a Vydac&'Clδ column
(8x300 ml) (isocratic elution with mobile phase 12% MeOH/0.1% TFA in water; flux : 2.5 ml/min. ; UV detection at 230 nm) . After HPLC, 40 mg of peptide are obtained.
Mass spectra FAB+ [M+H]+ : 661.4.
Aminoacids analysis : Glu (1) 1.06; Lys (1) 1.02; Arg (1) 1.06;
Pro (1) 0.85.
TLC in SI system. PHARMACOLOGICAL TESTS
Immunoadjuvant and immunostimulating activity evaluation
The following abbreviations are used :
PBS : phosphate buffer saline solution
FBS : fetal calf serum
RPMI -RPMI 1640 : Culture medium (Roswell Park Memorial
Institute)
TEST 1- Delayed hypersensitivity reaction to ovoalbumin in guinea pigs. 0.2 ml of a mixture composed of a physiological solution in an oily emulsion (Bayo±^: Arlace ^ : physiological solution 4 : 1 :
5) , containing 2 mg of crystalline ovoalbumin (FIA = Freund incomplete adjuvant) are injected into the pad of the left hind foot of albino female guinea pigs. The effect of oligopeptides A, B, C and D, which were added to the mixture in the amount of 100 μg, is compared with that of
Freund 's incomplete adjuvant (FIA) and with that of a known highly active bacterial adjuvant, Mycobacterium tubercolosis , contained in Freund' s complete adjuvant (FCA) . The cutaneous reaction is evaluated measuring the erythema diameter 14 days after the administration of 10 and 20 μg of ovoalbumin.
The so obtained erythema diameters, expressed in millimeters (mm), are reported in Table 1.
Table 1 Induction of delayed hypersensitivity to ovoalbumin in guinea pigs .
Ovoalbumine (dose) Ovoalbumine (dose)
Tested Dose 10 μg 20 μg
Substances
FIA - 1.4 ± 0.25 2.75 ± 0.47
A 100 μg 3.95 ± 0.40* 6.24 ± O.65*
B 100 μg 2.84 ± 0.34 4.80 ± O.56*
C 100 μg 4.22 ± 0.52* 7.55 ± 0.74*
D 100 μg 4.72 ± 0.62* 7.65 ± 0.82*
FCA 1 mg 3.25 ± 0.32* 6.12 ± O.56*
* P < 0.05
Results
As one can observe from Table 1, the administration of the oligopeptides A, B, C and D causes an increase of the delayed hypersensitivity reaction to ovoalbumine in guinea pigs and at the dose of 100 μg this effect is not only comparable to that of FCA but in certain cases (compound A, C and D) is even higher. TEST 2 GVHR (Graft-versus-host reaction)
Balb-c mice were divided in groups, each group of 4 animals, and utilized as splenocytes donors. Each group is treated by subcutaneous route with 100 μg of one compound selected from oligopeptides A, B or C or 1-aminoadamantane (AmAd) on days -2,
-1 and 0 before the induction of the regional GVHR. A control group is not treated with any of the above mentioned substances. On day 0, a suspension of aggregated spleen cells obtained from the donors is prepared by passing the cut spleens in a RPMI 1640 medium through a fine sieve. After centrifugation (800 x g, 8 min.), the spherical mass obtained is resuspended in RPMI 1640 up to obtaining the final o density of 1 x 10 /ml (only nucleated cells).
0.05 ml of the above mentioned suspension, containing 10 splenocytes are immediately injected into the pad of the left hind foot of hybrid F1 (C3H x Balb) ( 10 + 12 animals per group). 8 days after the injection, the weight of the popliteal lymphonodus both in the legs subjected to the injection and in the contralateral legs are evaluated. Their difference is taken as GHRV quantitative measure. The obtained data are reported in Table 2.
TABLE 2 Test of the graft-versus-host reaction (GVHR)
Control A B C D Am Ad
Lympho- 1.03*0.17 1.50*0.21 1.20*0.17 1.65*0.17 1-99*0.24 0.60*0.14 nodus in mg
Am Ad = 1 - aminoadamantane
Results
Compounds A, C and D resulted active, and among them the most active are compounds C and D.
TEST 3 - Hemoagglutination Sheep red blood cells (SRBC) are administered by intraperitoneal route to different mice groups in an amount of 5 x 10' in 0.50 ml
PBS for each animal and contemporaneously 100 μg oligopeptides A,
B, C or 1-aminoadamantane (AmAD) are administered by subcutaneous route. To the control group, no substance is administered. On the 5 day the mice are sacrificed by decapitation. Their serum is taken and heated to 56 °C for 30 min. in order to inactivate the complement.
Various serum dilution are prepared in PBS and an equal volume of
2% SRBC in PBS (volume/volume) is added. The so obtained samples are maintained at 4 °C for 18 hours before the final reading of the agglutination titre.
Titres are expressed as log2 of the highest serum dilution still showing agglutination.
In Table 3 reported are the hemoagglutination titres obtained after 5 days from the immunization.
Table 3 Total hemoagglutination titre after primary immunization with sheep red blood cells (SRBC) .
5 days after immunization
Control A B C D Am Ad
Total 2.43*0.18 2.78*0.18 3-21*0.18* 2.77*0.18 N.D. 2.68*0.09 titre
#
P < 0.05
N, . D . = not determined
Results
Compound B is the most active, inducing a significant increase in total hemoagglutination titre.
TEST 4 - Response of plaque forming cells (PFC) 100 μg oligopeptides A, B and C and 1-amino adamantane (AmAD) are administered together with SRBC by subcutaneous route to different mice groups immunized with SRBC (5 x 10' per animal, administered by intraperitoneal route) . The control group has not received the substances to be tested. A single cell splenocytes suspension (2 x 10 /ml) is obtained on the 5 day after immunization.
0.2 ml of said suspension are mixed with an equal SRBC volume (1 x 10-Vml) and with guinea-pig complement (diluted 1 : 10).
Every component is prepared in the RPMI 1640 medium.
The mixture is maintained in Cunningham chambers (0.1 ml) for 1 hour at 37 °C and at 100% relative humidity.
The number antibody-producing B-cells is evaluated as the PFC number per 10 splenocytes.
The obtained data are reported in Table 4.
Table 4 Plaque forming cells (PFC) number after primary immunization with sheep red blood cells (SRBC).
Control A B C D Am Ad
Number of 572*43 521±3δ 956*72 564*32 N.D. 657±27 PFC
** p < 0.01
N.D. = not determined
AmAd = 1-aminoadamantane
Results
As it can be seen from the obtained data, B is the only active compound in this test.
TEST - Splenocytes proliferation
According to Test 2, splenic cells are obtained from donors mice treated subcutaneously with 100 μg of the substances to be tested by passing their spleens cut in a RPMI 1640 medium through a fine sieve.
After centrifugation (800 x g, 8 min.) the obtained spheric mass
is resuspended in RPMI 1640.
The obtained splenic cells (0.2 ml per well with a density of 2.5 x 10 /ml) are cultured for 72 hours in FB** 96-wells microplates in the complete RPMI 1640 medium (10% FBS, 0.005% gentamicine) , at 37°C, with 5% C02 and 100% relative humidity, both in the absence or in the presence of mitogens CON A (concanavalin A)(l μg/ml) and LPS (lipopolysaccharide) (LPS S.typhy murium, Sigma^ (20 μg/ml). During the last 6 hours of culture, cells are collected and their radioactivity is determined by using a scintillation beta- counter.
The obtained data are summarized in table 5, which reports the effects of splenocytes proliferation, measured as thymidine-^H incorporation.
TABLE 5 Splenocytes polyclonal activation in vitro in the absence or in the presence of mitogens.
p.p.m. Control A B C Am A
Without mitogens 965*117 1557*205 1392*169 1790*249 1350*142 CON Ab ( 1 μg/mol ) 794*187 1791*264 2240*317 1852*223 1 38*296 LPSC (20 μg/mol ) 167 1*3874 22223*1797 31721*5104 21864*3957 21944*4921
apulsation per minute clipopolysaccharide concanavalin A 1-aminoadamantane
Results
All the tested oligopeptides are active in promoting splenocytes proliferation.
In the absence of mitogens, the most active compound is C. All compounds increase the mitogenic answer to CON A, nevertheless B results to be the most active compound.
Compound B is the most active also in increasing the mitogenic answer to LPS. Because LPS is considered to be a specific mitogen for B-cells and CON A for T-cells, the test shows an action specificity of the tested compounds versus B and T cells.
TEST 6- Pyrogenicity.
The pyrogenic effect of the above mentioned derivatives A, B, C and D is determined on rabbits having a weight of from 2 to 2.3 kg. The compounds are injected by intravenous route and the effect is compared with that obtained with muramyl dipeptide
(MDP), a very powerful pyrogenic adjuvant. Temperature is measured by a rectal thermistor thermometer every hour.
Results are shown in Table 6. The reported values are the average of values obtained from groups of 5 animals.
TABLE 6 Pyrogenic effect of the tested compounds Temperature (°C)
Tested Dose 1 h 2 h 3 h 4 h 5 h substances
Controls - + 0.2 - 0.2 - 0.1 + 0.2 0
A 1 mg + 0.3 + 0.4 - 0.2 + 0.3 + 0.2
B 1 mg - 0.2 0 + 0.3 - 0.2 + 0.1
C 1 mg + 0.1 0.3 + 0.4 + 0.4 + 0.2
D 1 mg - 0.2 0 + 0.2 + 0.1 - 0.2
MDP 100 μg + 0.9 1.6 1.2 1.2 0.7
Conclusions
The results obtained in these pharmacological tests highlight the quite different effects on the humoral and on the cell mediated immunity of the tested compounds.
For example, Compound B proves to be the most active in the stimulation of the humoral activity in both TESTS 3 and 4.
On the other side, all the tested compounds are active in stimulating cellular immunity. Among them, B compound has however the lowest activity, while C and D have a remarkable effect (as it can be seen from TESTS 1 and 2 which evaluate the cellular immunity) .
Moreover after the administration of the tested oligopeptides no pyrogenic effect and no toxicity sign are observed on animals.
The pyrogenicity test is very significant because pyrogenicity is generally connected with I Interleukin release and therefore with a series of side effects determined by that substance. Test 7 ~ Effect of D compound in Lewis Lung Carcinoma (LLC) Materials and methods
C 57 Bl/6 (Charles River) female mice were used, weighing on average 20 g.
LLC (Lewis Lung Carcinoma) tumoral cells were obtained from animals affected by the transplanted tumor (16 passage). This tumor was subcutaneously transplanted into the axillary region. The total number of transplanted cells was 2X10-5 in 0.1 ml of Hanks solution.
Compound D was dissolved in physiological solution and intraperitoneally (i.p.) administered at the dose of 15 mg/kg to groups of at least 10 mice, by following different protocols of treatment.
Described are hereinbelow the groups of treated animals, the day in which they received the specific treatment, and the received treatment protocol (the day 0 is that in which the tumoral cells transplant was conducted; the day -3 corresponds to 3 days before this transplant and +3 means 3 days after the same) .
Group 1 (control) day -3 : physiological solution day 0 : physiological solution + tumoral cells day +3 : physiological solution
Group 2 (3x peptide D) day -3 peptide D day 0 peptide D + tumoral cells day +3 peptide D
Group 3 (2x peptide D) day -3 peptide D day 0 peptide D + tumoral cells day +3 physiological solution
Group 4 (2x peptide D) day -3 physiological solution day 0 peptide D + tumoral cells day +3 peptide D
Group 5 (lx peptide D) day -3 : physiological solution day 0 : peptide D + tumoral cells day +3 : physiological solution
On days 7,10 and 15, from tumoral cells inoculation, the tumoral growth was determined by palpation and evaluated by using the
"scoring" method, classifying the tumor as "large" or "small"
(see Table 7) .
On day 17 from tumoral cells inoculation, the animals were sacrificed, tumors were removed and weighed (see Table 8); lungs were examined by a histologist and metastases counted (see Table
9)
Results
The results obtained in the Lewis Lung carcinoma model, show the effect of compound D both on the primary tumor and on the blood born metastases. The data reported in Table 7 show that when Compound D is administered three times (15 mg/kg) , respectively on days -3, 0 and 3, (Group 2), it significantly reduces the tumor growth as assessed through the scoring method on days 7, 10 and 1 . When compound D is administered however only twice (Group 3 and 4) or once (Group 5), no statistically significant results are obtained.
The data relating to the tumor weight after mice sacrifice (on day 17) , show that in the mice treated with Compound D under all the different protocols (Groups 2, 3. 4 and 5). the tumor average weight is always lower than in the control group (Group 1), though not reaching statistical significance.
Table 8 reports in particular the data on tumor weight, obtained by administering Compound D three times (3x) (Group 2), in comparison with the control group (Group 1). The results relating to lung metastases formation are the most important, since they show that Compound D is able to significantly reduce metastases incidence at lung level, some animals being free of metastases. The data of Table 9 concern in particular the metastases number observed in mice treated three times with Compound D (Group 2) in
comparison with the control group (Group 1)
TABLE 7 Evaluation of the tumor by palpation, after 3 administrations (3x) of compound D according to Group 2 protocol. Tumor growth on day 7 from inoculation
Group 1 (control) Group 2 (3x compound D) mice No. mice % mice No. mice % large 10 83-3 3 27.3 small 2 16.7 8 72.7 chi-square 9-8 P < 0.01
Tumor growth on day 10 from inoculation
Group 1 (control) Group 2 (3x compound D) mice No. mice % mice No. mice % large 10 83-3 4 36.4 small 2 16.7 7 63.6 chi-square 3-8 P < 0.05
Tumor growth on day 15 from inoculation
Group 1 (control) Group 2 (3x compound D) mice No. mice % mice No. mice % large 12 100 9 81.8 small 0 0 2 18.2 chi-square 6.2 P < 0.05
Notes :
* = statistically significant datum. p = corresponds to the probability level for rejection of 0 hypothesis
TABLE 8 Tumor weight (grams) after administration of compound D (15 mg/kg; three times; on days: -3, 0,+3)
Group 1 Group 2
(control) (3x compound D) tumor weight (g) tumor weight (g)
Treatc 3d animals
1 (dead) 1.08
2 3-94 3-59
3 4.2 4.2
4 3-95 3-5
5 3.16 4.07
6 4-3 3.02
7 4.49 3-3
8 3-05 2.93
9 3-49 2.9
10 3-35 4.39
11 3.68 2.3
12 3-34 -
Sum 40.95 35-28
Average 3-72 3-21
SEM 0.15 0.28
Notes:
SEM = Standard error mean
Group 2 consists of 11 mice.
TABLE 9 Number of lung metastases after compound D administration (15 mg/kg; three times; on days: -3, 0.+3)
Group 1 Group 2 (control) (3x compound D) No. of metastases No. of metastases Treated animals
1 (dead) 0
2 1 0
3 3 0
4 4 0
5 4 3
6 4 4
7 4 5
8 10 5
9 12 6
10 15 9
11 18 9
12 20
Sum 95 41
Average 8.64 3-73
SEM 2.1 1.05
% mice free from metastases 0 36.4
% mice with metastases 100 63-6 chi- square
Notes:
SEM = Standard error of mean
Group 2 consists of 11 mice
* = statistically significant datum
Test 8 - Macrophages Nitric Oxide (NO) production
Female mice of inbred strain Balb/c were used.
Compounds used and administration routes:
Compound D, sub-cutaneous injection
Physiological saline solution (saline) , sub-cutaneous injection
Lipopolysaccharide (LPS): S. typhy murium (Sigma), added to macrophages culture medium.
LPS is a substance known for its ability to activate N0- synthetase enzyme and therefore to activate NO production.
The control Group was made of 12 animals, divided in 2 sub-groups of 6 animals each.
Sub-group 1: was injected with saline, then macrophages culture.
Sub-group 2: was injected with saline, then macrophages culture in presence of LPS 5 U-
The Treated Group was made of 12 animals, divided in 2 sub-groups of 6 animals each.
Each animal got a single 200 μg sub-cutaneous injection of
Compound D on day -1 prior to the macrophages cells isolation and assay of Nitric Oxide production.
Sub-group 3: Compound D 200 μg (-Id), then macrophages culture. Sub-group 4: Compound D 200 μg (-Id), then macrophages culture in presence of LPS 5 P- Macrophages culture conditions:
Peritoneal macrophages were isolated and cultivated in Nunc 96- well FB-microplates in RPMI-1640 medium (10% FBS, 0.005% Gentamycin, 0.05 μM 2-Mercaptoethanol) under the following conditions: 37°C, 5% C02, 100% relative humidity, 24 hours. Griess reagent was used to determine spectrophotometrically nitrite levels, carrying out the detection at 5 θ nm with an Uniscan II reader. The obtained results are reported in Table 10 here below:
TABLE 10
Cell Sub- Control Sub- Treated culture Group (saline) Group 1 x 200 μg (-Id)
- 1 AVG 0.014 3 AVG -0.008 NS SEM 0.01 SEM 0.003
LPS 2 AVG 0.031 4 AVG 0.251 ♦#*
5μg SEM 0.001 SEM 0.015
- *#*
Notes :
- Nitrogen Oxide (NO) production is expressed as nitrites amount, which is in turn expressed as optical density at 540 nm (OD 540 nm) . - Average (AVG) is calculated on the results obtained on 6 animals.
- SEM = Standard Error of Mean. Results
These data show that Compound D is able, under certain conditions, to stimulate NO production by macrophages. On single dose of 200 μg/animal given 24 hours before assay markedly increased the LPS stimulatory effect on NO production.
Claims
CLAIMS 1. Oligopeptides derivatives endogenous leukokinin fragments containing at least one L-Glu(NH-Ad) residue and their pharmaceutically acceptable salts. 2. The oligopeptides as claimed in claim 1 containing from 1 to 3 L-Glu(NH-Ad) residues. 3- The oligopeptides as claimed in claim 2, containing from 1 to 3 L-Glu(NHAd) residues, at least a Lys residue and at least one residue selected from the group consisting of Arg, Pro and Pro- Ar - 4. The oligopeptides as claimed in claim 1, formed by a number of from 4 to 5 aminoacids. 5- The oligopeptides as claimed in claim 1, selected from the group consisting of: H-Lys-Glu(NH-Ad)-Pro-Arg-Glu(NH-A )-OH, H-Lys-Glu(NH-Ad) -Arg-Glu(NH-Ad) -OH , H-Lys-Glu(NH-Ad) -Pro-Glu(NH-Ad) -OH and H-Glu(NH-Ad) -Lys-Pro-Arg-NH2 6. A process for preparing oligopeptide, derivative of endogenous leukokinin fragments containing at least one L-Glu (NH-Ad ) residue, comprising the following steps : a) condensing on a resin the first aminoacid protected at the α- amino group with P^ , wherein P-^ is a protecting group of the α- amino group selected from the group consisting of terbutoxycarbonyl (Boc) and fluorenylmethyloxycarbonyl (Fmoc) , by
8 treating a resin with chloromethyl groups, with the Cesium salt
9 of the above mentioned protected first aminoacid, in a polar 20 aprotic solvent at a temperature comprised between +40 and +90°C,
11 preferably between +60° and +70 C; or by treating a resin with p-
12 methylbenzhydrylamino groups with the above first aminoacid
13 protected at the α-amino group, after treating it with a compound
14 P OH known for the activation of the aminoacid α-carboxy group;
15 in the presence of a dialkylcarbodiimide, at room temperature
16 (about +20%°C - +30%°C) ;
17 b) removing the above mentioned protecting group Pi from the
18 amino acid supported on the resin obtained in a), by treatment, ^9 when P^ is Boc, with trifluoroacetic acid, at a temperature
20 comprised between 0 and +50 C, followed by neutralization with a
21 base (an alyphatic tertiary amine substituted with C -Cg alkyl
22 groups), and when P^ is Fmoc, with a solution of a saturated
23 heterocyclic amine in an organic solvent when P-. is Fmoc;
24 c) assembling onto the resin the next aminoacid protected at the 2f- alpha-aminogroup with P-^, where P^ is above defined, in an „_ organic solvent at a temperature comprised between 0 and +50 °C, _„ after treating said successive aminoacid with P20H, where P20H is
28 a hydroxy compound known for the activation of the aminoacid
29 carboxy group, in the presence of a condensing agent, at a
30 temperature comprised between 0 and +50 °C, preferably between
31 +20 °C and +30 °C;
32 d) removing as in step b) the protecting group P^ and the other
Boc or Fmoc groups possibly present in the lateral chain of the peptide supported on the resin obtained in step c) ; e) cleaving the final oligopeptide from the polymeric support by means of treatment with liquid HF, at a temperature between -20° and 0°C, in the presence of a "scavenger", followed by the recovery of the thus obtained oligopeptide. 7- A process as claimed in claim 6, wherein said oligopeptide derivative is selected from the group consisting of H-Lys-Glu(NHAd)-Pro-Arg-Glu(NHAd)-OH, H-Lys-Glu(NHAd)-Arg-Glu(NHAd)-OH and H-Lys-Glu(NHAd)-Pro-Glu(NHAd)-OH, the resin has chloromethyl groups, the first aminoacid protected at the α-amino group with P-^ is Boc-Glu(NHAd) , the cesium salt is obtained by reacting said first protected aminoacid with cesium carbonate, in a hydroalcoholic medium, at room temperature, then evaporating the solvent to dryness, the solvent in step a) is dimethylformamide, the temperature in step a) is +6θ°C - +70°C; in step c) , P 0H is N-hydroxybenzotriazole, the condensing agent is diisopropylcarbodiimide, the solvent of step c) is a dichlorometane/dimethylformamide mixture the temperature in step c) is +20°C - +30°C; in step e) the scavenger is a thioanisole-p- thiocresol mixture; the cleavage of Boc and Fmoc groups according to steps b) and d) is carried out in the case of Boc groups with 40%-60% solution of trifluoroacetic acid in an halogenated solvent, at a temperature of +20°C - +30°C, followed by
20 neutralization with ethyldiisopropylamine; in the case of Fmoc
21 groups, piperidine in dimethylformammide at +20°C - +30°C is
22 used.
I 8. A process as claimed in claim 6, wherein said oligopeptide
2 derivative is
3 H-Glu(NHAd)-Lys-Pro-Arg-NH2, the resin has p-methylbenzydrylamino groups, the first aminoacid
5 protected at the α-amino group with Pχ is Fmoc-Arg(Mtr)-OH, in
6 step a) and c), P 0H is N-hydroxybenzotriazole, the condensing
7 agent is diisopropylcarbodiimide, the solvent in step a) and c) is dimethylformamide, the temperature in step a) and c) is +20°C - +30°C; in step e) the scavenger is a thioanisole-p-thiocresol ° mixture; the cleavage of Boc and Fmoc groups according to steps b) and d) is carried out in the case of Boc groups with a 4θ%-6θ% 2 solution of trifluoroacetic acid in an halogenated solvent, at a 3 temperature of +20°C - +30°C, followed by neutralization with 4 ethyldiisopropylamine; in the case of Fmoc groups, piperidine in 5 dimethylformammide at +20°C - +30°C is used. 9- Therapeutic compositions comprising as the active principle a therapeutically effective amount of at least one oligopeptide derived from fragments of endogenous leukokinin containing at least one L-Glu(NH-Ad) residue , or a pharmaceutically acceptable salt thereof, in combination with other excipients. 10. The therapeutic compositions as claimed in claim 9. useful in the human therapy for the treatment or the prophylaxis of
diseases associated with a deficit in immune response. 11. The therapeutic compositions as claimed in claim 10, wherein these diseases are selected from the group consisting of tumours, and infections. 12. The therapeutic compositions as claimed in claim 9, comprising, besides this oligopeptide, one or more therapeutically active substances whose activity is enhanced by this oligopeptide. 13- The therapeutic compositions as claimed in claim 12, wherein these therapeutically active substances are provided with antigenic properties and are contained in vaccines. 14. The therapeutic compositions as claimed in claim 9, suitable to be orally administered. 15. The therapeutic compositions as claimed in claim 9, suitable to be parenterally administered. 16. The therapeutic composition as claimed in claim 9, wherein this oligopeptide has an arginine residue at the extreme C- terminal, said compositions being useful in the human therapy in the treatment of pathologies of the nervous system, of the immune system and in vascular diseases. 17. The therapeutic compositions as claimed in claim 16, wherein said pathologies are selected among tumors, autoimmune diseases, diseases linked with neurotransmission disturbances. 18. The therapeutical compositions as claimed in claim 16, wherein this oligopeptide is H-Glu(NH-Ad)-Lys-Pro-Arg-NH2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI930724 | 1993-04-09 | ||
IT93MI000724A IT1264129B1 (en) | 1993-04-09 | 1993-04-09 | PEPTIDES WITH IMMUNOMODULATORY ACTIVITY DERIVED FROM LEUCOQUININ FRAGMENTS |
PCT/EP1994/001099 WO1994024154A2 (en) | 1993-04-09 | 1994-04-08 | Immuno modulated peptide derivatives of leukokinin fragments |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0693082A1 true EP0693082A1 (en) | 1996-01-24 |
Family
ID=11365734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94913125A Ceased EP0693082A1 (en) | 1993-04-09 | 1994-04-08 | Immuno modulated peptide derivatives of leukokinin fragments |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0693082A1 (en) |
IT (1) | IT1264129B1 (en) |
WO (1) | WO1994024154A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2107691C1 (en) * | 1995-03-02 | 1998-03-27 | Дейгин Владислав Исакович | Peptide and method for its preparation |
US6126939A (en) * | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
WO2006118327A1 (en) * | 2005-04-27 | 2006-11-09 | Oxygenix Co Ltd | Cationic amino acid type lipid |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2617646C2 (en) * | 1976-04-22 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Nonapeptide-amides and decapeptide-amides with gonadoliberin activity, processes for their preparation and pharmaceutical preparations containing these compounds |
DE2945239A1 (en) * | 1979-11-09 | 1981-05-21 | Troponwerke GmbH & Co KG, 5000 Köln | Antiinflammatory oligopeptide derivs. for e.g., rheumatism - contg. protected amino acid gp., attached to a lysine-proline-arginine tri:peptide chain |
CS231221B1 (en) * | 1982-06-29 | 1984-10-15 | Martin Flegel | L-alanyl-d-isoglutamine adamantylamide |
DK0668290T3 (en) * | 1990-02-28 | 1999-07-26 | Teikoku Seiyaku Kk | Physiologically active substance capable of permeating the biomembrane |
-
1993
- 1993-04-09 IT IT93MI000724A patent/IT1264129B1/en active IP Right Grant
-
1994
- 1994-04-08 EP EP94913125A patent/EP0693082A1/en not_active Ceased
- 1994-04-08 WO PCT/EP1994/001099 patent/WO1994024154A2/en not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
AL 'PHARMACOKINETIC PROFILE OF THE IMMUNOMODULATING COMPOUND ADAMANTYL DIPEPTIDE(AdDP), A MURAMYL DIPEPTIDE DERIVATIVE IN MICE' cited in the application * |
IMMUNOPHARM. AND IMMUNOTOX., vol.13, no.1&2, 1991 pages 101 - 119 P.WALDER ET * |
Also Published As
Publication number | Publication date |
---|---|
ITMI930724A1 (en) | 1994-10-09 |
WO1994024154A2 (en) | 1994-10-27 |
WO1994024154A3 (en) | 1994-12-22 |
IT1264129B1 (en) | 1996-09-16 |
ITMI930724A0 (en) | 1993-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Siemion et al. | Tuftsin: on the 30-year anniversary of Victor Najjar’s discovery | |
Metzger et al. | Synthesis of novel immunologically active tripalmitoyl‐S‐glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations | |
REITERMANN et al. | Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten | |
Werner et al. | Immunomodulating peptides | |
Metzger et al. | Lipopeptides containing 2-(palmitoylamino)-6, 7-bis (palmitoyloxy) heptanoic acid: synthesis, stereospecific stimulation of B-lymphocytes and macrophages and adjuvanticity in vivo and in vitro | |
RU2107692C1 (en) | Peptide and method for its preparation | |
DE69024230T2 (en) | AMINO ACIDS, PEPTIDES OR DERIVATIVES BONDED TO FATS | |
Migliore-Samour et al. | A short lipopeptide, representative of a new family of immunological adjuvants devoid of sugar | |
US5583198A (en) | Amino acids, peptides or derivatives thereof coupled to fats | |
US4113858A (en) | Novel compounds, compositions and methods of their use | |
US6074650A (en) | Membrane anchor/active compound conjugate, its preparation and its uses | |
US4461761A (en) | Oligomers of compounds of the muramyl-peptide type and medicaments containing them | |
US6024964A (en) | Membrane anchor/active compound conjugate, its preparation and its uses | |
JP3821305B2 (en) | Cytotoxic T lymphocyte-derived lipopeptides and vaccines | |
US5416070A (en) | Composition for macrophage activation | |
AU705418B2 (en) | Peptides having immunomodulatory activity | |
WO1990000396A1 (en) | Composition for macrophage activation | |
WO1994024154A2 (en) | Immuno modulated peptide derivatives of leukokinin fragments | |
IT9019914A1 (en) | IMMUNOGENIC COMPOUNDS, THE PROCEDURE FOR THEIR SYNTHESIS AND THEIR USE FOR THE PREPARATION OF ANIMALARY VACCINES | |
US4693998A (en) | Novel compounds of the muramyl peptide | |
US20200399311A1 (en) | Novel peptide based pcsk9 vaccine | |
AU671118B2 (en) | Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds | |
EP0604945A1 (en) | TAN-1511, its derivatives, production and use thereof | |
TITOV et al. | Synthesis and immunological evaluation of the conjugates composed from a muramyl peptide GMDP and tuftsin | |
US5225530A (en) | Polypeptide useful for the preparation of antimalarial vaccines and of diagnostic kits for the detection of malarial affections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951106 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 19960812 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19970131 |